The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia

Chia-Jen Liu1,2,3 | Ying-Chung Hong3,4 | Ai Seon Kuan2,5 | Chiu-Mei Yeh1,2 | Chun-Kuang Tsai1 | Yao-Chung Liu1,3 | Liang-Tsai Hsiao1,3 | Hao-Yuan Wang1,3 | Po-Shen Ko1,3 | Po-Min Chen1,3 | Jin-Hwang Liu1,6,7 | Jyh-Pyng Gau1,3

1Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
2Institute of Public Health, National Yang-Ming University, Taipei, Taiwan
3School of Medicine, National Yang-Ming University, Taipei, Taiwan
4Division of Hematology and Oncology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
5Division of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
6Division of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan
7Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University, Taipei, Taiwan

Correspondence
Chia-Jen Liu, Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, No. 201 Shipai Road, Sec. 2, Taipei, Taiwan 11217.
Email: chiajenliu@gmail.com

Funding information
Taipei Veterans General Hospital, Grant/Award Number: V105E10-002-MY2-1, V105B and -016; Ministry of Science and Technology, Grant/Award Number: MOST 104-2314-B-075-085- and MY2 and MOST 105-2314-B-418-003-MY3; Taiwan Clinical Oncology Research Foundation; Szu-Yuan Research Foundation of Internal Medicine; Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University; Yen Tjing Ling Medical Foundation

Abstract

Background: Acute myeloid leukemia (AML) is a common hematologic neoplasm with high incidence and mortality in the elderly. Our aims were to explore risk factors for early mortality in elderly AML patients and develop a new prognostic score.

Methods: We enrolled newly diagnosed AML patients age 60 and above at Taipei Veterans General Hospital between July 2008 and May 2017. The primary endpoint was early mortality, defined as death within two months after AML diagnosis. A multivariate Cox proportional hazards model was used to build a risk-scoring system incorporating significant risk factors for AML.

Results: The final cohort included 277 elderly AML patients. The median age was 74 (range 60-96), and 61.7% were male. The two-month mortality rate was 29.9%. Age ≥ 80 (adjusted HR 1.88), myocardial infarction (adjusted HR 1.87), ECOG ≥ 2 (adjusted HR 2.10), complex karyotype (adjusted HR 3.21), bone marrow blasts ≥ 70% (adjusted HR 1.88), WBC ≥ 100 × 10⁹/L (adjusted HR 3.31), and estimated glomerular filtration rate (eGFR) < 45 (adjusted HR 2.60) were identified as independent predictors for early mortality in the multivariate analysis. A simplified score incorporating the seven factors was developed with good predictive ability measured by Harrell’s C statistic [0.72 (95% CI 0.66-0.78)].

Conclusions: We identified seven potential risk factors for early mortality and built up a new prognostic score for elderly AML patients. The new score may help clinicians stratify patients and initiate appropriate management. Further validation of our findings on other cohorts is warranted.

KEYWORDS
acute myeloid leukemia, elderly, early mortality, epidemiology, prognostic models
Acute myeloid leukemia (AML) is a hematological neoplasm commonly seen in Taiwan and many other countries.1,2 The estimated number of new cases was 21450 in the US in 2019.3 The median age of AML patients at diagnosis is about 70 years old.4 The median progression-free survival (PFS) and overall survival (OS) of elderly AML patients (age ≥ 60) receiving standard induction treatment (7 + 3, cytarabine with an anthracycline) were 6.7 and 14.7 months, respectively.5 In elderly patients receiving hypomethylating agents (HMAs), the median PFS and OS were only 4.1 and 4.3 months, respectively. The high mortality in elderly AML patients was reported to be associated with old age, poor performance status, and disease characteristics such as high-risk cytogenetics and complex karyotypes.5-8

Because the characteristics and outcomes of AML are very heterogeneous, several risk stratification systems have been developed. Malfuson et al reviewed 416 elderly patients treated in the ALFA-9803 trial in France and identified high-risk cytogenetics and the presence of at least two of the three factors (age ≥ 75, performance status ≥ 2, white blood cell (WBC) ≥50 × 10^9/L) attributed to OS.5 Wheatley et al analyzed 2483 AML patients age ≥ 60 enrolled in two UK trials—the Medical Research Council AML11 Trial and the Leukaemia Research Fund AML14 Trial.6 They built up a risk score using cytogenetics, WBC, performance status, age, and AML type. Kantarjian et al found that intensive chemotherapy did not benefit most elderly AML patients (age ≥ 70). They identified age ≥ 80, complex karyotypes, poor performance and elevated creatinine > 1.3 mg/dL as independent predictors for eight-week mortality.7 Walter et al reviewed 2238 adults treated at MD Anderson Cancer Center and 1127 patients from 10 SWOG trials. They found that old age, poor performance status, and low platelet count were risk factors of early death after induction therapy for newly diagnosed AML.8 Ramos et al conducted a retrospective study (ALMA Registry) in Spain and developed the European ALMA score (using ECOG, WBC, and cytogenetics) to predict OS of unfit AML patients treated with an HMA.

The scoring systems mentioned above were developed in the US and European countries. They might not be suitable for predicting outcomes of our population due to differences in ethnicity and healthcare systems. We hence investigated risk factors for early mortality in elderly AML patients and aimed to develop a new scoring system, combining clinical data and genetic abnormalities, to predict outcomes of elderly AML patients in Asian populations.

This study included consecutive elderly patients with newly diagnosed AML between 1 July 2008 and 31 May 2017 at Taipei Veterans General Hospital. Follow-up was continued to 31 July 2017. AML was diagnosed based on WHO criteria,9 and bone marrow (BM) examinations were performed at diagnosis. Patients younger than 60 and those without a pathologic diagnosis were excluded.

Data collection was performed by reviewing medical records. The following clinical characteristics were obtained: age, sex, height, weight, and smoking status; comorbidities, including diabetes mellitus, hypertension, myocardial infarction, and ulcer diseases; laboratory parameters, including white blood cells with differential counts, hemoglobin, platelets, and blasts in peripheral blood and BM; performance status according to the Eastern Cooperative Oncology Group performance score (ECOG)10,11; genetic risk status, including cytogenetics and molecular abnormalities12; which was recorded at diagnosis. Having an antecedent hematologic disorder was defined as having a history of specifically myelodysplastic syndromes, myeloproliferative neoplasms, or aplastic anemia.13

Cutoff values for age, performance status, WBC, platelet, cytogenetics, creatinine, and AML type were chosen according to those of the previous studies.5-8,14-16 The estimated glomerular filtration rate (eGFR) was calculated based on Chronic Kidney Disease Epidemiology Collaboration Equations.17,18

Information on treatment regimens composed of induction and consolidation treatment was collected. Intensive treatment was defined as cytarabine with an anthracycline treatment or high-dose cytarabine. Supportive care was defined as low-dose cytarabine, hydroxyurea, or no AML-specific treatment with blood transfusion.

Our primary endpoint was early mortality, defined as death within 60 days after AML initial diagnosis.19 Our retrospective review of medical records was conducted in accordance with the institutional ethics committee and in agreement with the Helsinki Declaration of 1975, revised in 2008. This study was approved by the Institutional Review Board at Taipei Veterans General Hospital (No. 2019-05-009BC).
categorical data, and medians and interquartile ranges (IQR) for continuous data (skewed).

Data for patients who did not have early mortality or who were lost to follow-up were censored. In the survival analysis, the Kaplan-Meier method was used for estimation of cumulative incidence of early mortality, and differences between groups were tested by log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models, controlling for potential confounding factors in the multivariate model. We first used a univariate model to identify potential risk factors for AML early mortality. All risk factors with \( P < .1 \) in the univariate model were further entered into the multivariate analysis. All independent risk factors identified in the multivariate analysis were then used to build a predictive model of early mortality.

The \( \beta \)-coefficients of all significant risk factors in the multivariate Cox proportional hazards model were used to build a new risk-scoring system. We also built a simplified score by assigning one point to each significant variable. Model discrimination was estimated by Harrell’s C statistics. The discriminatory ability of our score and existing prognostic scores identified by a systematic review were compared using the Akaike information criterion (AIC) and Bayesian information criterion (BIC) calculations.

Data management and all statistical analysis were performed using SAS 9.4 software (SAS Institute Inc) and STATA statistical software, version 15.1 (StataCorp). All statistically significant levels were set at \( P < .05 \).

3 | RESULTS

3.1 | Clinical characteristics of the study population

A total of 478 patients with newly diagnosed AML between 1 July 2008 and 31 May 2017 at Taipei Veterans General Hospital were identified. Patients who had no pathological confirmation (\( n = 5 \)) and those diagnosed at age < 60 (\( n = 196 \)) were excluded. Finally, 277 elderly AML patients were enrolled in the study. The median age was 74 (range 60-96), and 61.7% were men. Ninety-four patients (33.9%) had secondary AML. Hypertension (45.9%) and diabetes mellitus (33.6%) were the most common comorbidities. In regards to cytogenetics and molecular abnormalities, 13.0%, 48.0%, and 33.9% had favorable, intermediate, and poor/adverse risk, respectively. The median of BM blasts was 80%, and 66.2% of the patients also had the presence of blasts in their peripheral blood. The initial treatment was categorized into cytarabine-based intensive treatment, azacitidine or decitabine, all-trans retinoic acid, and supportive care, which were 32.1%, 18.8%, 2.9%, and 46.2% of 277 patients, respectively (Table 1).

3.2 | Risk factors of early mortality

The median OS was 5.1 (95% CI 3.5-6.4) months from diagnosis of AML. The probability of survival within 2 months was 70.1% (95% CI 64.1-75.2%). The cumulative probability of the death curve is shown in Figure 1. In the univariate analysis, we found that age \( \geq 80 \), having an antecedent hematologic disorder, myocardial infarction, ulcer diseases, ECOG performance status \( \geq 2 \), complex karyotype, BM blasts \( \geq 70\% \), WBC count \( \geq 100 \times 10^9/\text{L} \), and eGFR < 45 were associated with early mortality in patients with AML (Table 2). In the multivariate analysis, age \( \geq 80 \) (adjusted HR 1.88, 95% CI 1.08-3.30), myocardial infarction (adjusted HR 1.87, 95% CI 1.08-3.24), ECOG \( \geq 2 \) (adjusted HR 2.10, 951.22-3.63), complex karyotype (adjusted HR 3.21, 95% CI 1.80-5.71), BM blasts \( \geq 70\% \) (adjusted HR 1.88, 95% CI 1.07-3.32), WBC \( \geq 100 \times 10^9/\text{L} \) (adjusted HR 3.31, 95% CI 1.59-6.90), and eGFR < 45 (adjusted HR 2.60, 95% CI 1.54-4.39) remained statistically significant (Table 2).

3.3 | Risk stratification for elderly AML patients

We built a prognostic model incorporating all independent risk factors. The \( \beta \)-coefficients of all significant variables in the multivariate analysis were used to create the prognostic index for early mortality. The resulting equation is as follows:

\[
\text{Index} = 0.63 \times \text{age} + 0.63 \times \text{myocardial infarction} + 0.74 \times \text{ECOG} + 1.16 \times \text{complex karyotype} + 0.63 \times \text{BM blasts} + 1.20 \times \text{WBC} + 0.96 \times \text{eGFR} < 45
\]

The median index in all participants was 1.4 (IQR 0.6-2.3). Each increment in the index was associated with a nearly three-times increase in hazard for early mortality (HR 2.70, 95% CI 2.06-3.53). The prognostic index discriminated the risk of early mortality in elderly AML patients with an estimated Harrell’s C statistic of 0.74 (95% CI 0.68-0.81). A simpler risk model may be easier to use in clinical practice. Thus, we defined a simplified prognostic model by assigning one point for each of the seven independent predictors (age \( \geq 80 \), myocardial infarction, ECOG \( \geq 2 \), complex karyotype, BM blasts \( \geq 70\% \), WBC \( \geq 100 \times 10^9/\text{L} \), and eGFR < 45). Then we divided
the patients into low-risk (score 0-1), intermediate-risk (score 2-3), and high-risk (score 4-5) groups, based on the scoring of the simplified model. The numbers of patients belonging to low-, intermediate-, and high-risk groups were 91 (37.0%), 118 (48.0%), and 37 (15.0%), respectively (Table 3).

The Kaplan-Meier curves demonstrate that patients with higher scores had significantly shorter survival (log-rank test $P < .001$) (Figure 2). The HR for the intermediate- and high-risk groups were 3.01 (95% CI 1.43-6.33) and 12.04 (95% CI 5.60-25.92), respectively, when compared with the low-risk group. The predictive ability of the simplified model measured by Harrell's C statistic was 0.72 (95% CI 0.66-0.78).

### 3.4 Comparisons with different scoring systems

We systematically reviewed existing prognostic models for elderly AML. We found five scoring models that do not require additional specific examinations and later applied them to our elderly AML cohort. Supplemental Table 2 lists the performance of our model and the other five models. The median Malfluson index was 9.5 (IQR 5.8-39.7). The index could not predict early mortality in our cohort. However, the simple decisional index had better performance (HR 3.03, 95% CI 1.72-5.32 for score 1 and 3.19, 95% CI 1.49-6.81 for score 2, respectively). The Wheatley index and its simplified risk score identified the poor-risk group with a significant higher risk of early mortality (HR 3.43, 95% CI 1.47-7.96 for index and HR 3.49, 95% CI 1.40-8.71 for simplified risk score, respectively) although the probability of early mortality was similar between good and standard risk groups. Kantarjian’s prognostic model divided the patients into
four groups.⁷ The patients with two or ≥ three adverse factors had significantly high risk of early mortality (HR 3.35, 95% CI 1.53-7.31 for score 2 and 7.08, 95% CI 3.22-15.58 for score ≥ 3 adverse factors, respectively). Another two scoring models purposed by Ramos, Walter, et al predicted early mortality in the high-risk group but had no significant difference between low- and intermediate-risk groups.⁸,¹⁴ Our prognostic model had the highest Harrell’s C statistic and the lowest AIC and BIC compared with the other five prognostic models.

### TABLE 2  
Risk factors for early mortality in elderly patients with newly diagnosed acute myeloid leukemia

| Predictive variables                  | n     | No. of events | Univariate analysis | Multivariate analysisa |
|--------------------------------------|-------|---------------|---------------------|------------------------|
|                                      |       |               | HR (95% CI)         | P value                |
|                                      |       |               | HR (95% CI)         | P value                |
| Age ≥ 80                             | 96    | 36            | 1.80 (1.16-2.80)    | .009                   |
| Sex (male)                           | 171   | 52            | 1.20 (0.76-1.91)    | .436                   |
| Secondary AML                        | 94    | 31            | 1.27 (0.81-1.99)    | .307                   |
| Therapy-related AML                  | 25    | 10            | 1.59 (0.82-3.09)    | .169                   |
| Antecedent hematologic disorder      | 42    | 17            | 1.67 (0.98-2.85)    | .062                   |
| AML-MRC                              | 82    | 24            | 0.97 (0.60-1.56)    | .897                   |
| APL                                  | 11    | 2             | 0.58 (0.14-2.36)    | .446                   |
| Comorbidities                        |       |               |                     |                        |
| Diabetes mellitus                    | 93    | 23            | 0.80 (0.49-1.30)    | .370                   |
| Hypertension                         | 127   | 38            | 1.10 (0.71-1.72)    | .660                   |
| Myocardial infarction                | 54    | 21            | 1.60 (0.97-2.64)    | .065                   |
| Ulcer disease                        | 45    | 17            | 1.58 (0.92-2.71)    | .094                   |
| ECOG ≥ 2                             | 116/270 | 46          | 2.73 (1.71-4.38)    | <.001                  |
| Cytogenetics and molecular abnormalities |     |               |                     |                        |
| NPM1                                 | 20/125 | 2             | 0.39 (0.09-1.64)    | .199                   |
| FLT3-ITD                             | 18/125 | 4             | 1.11 (0.39-3.22)    | .841                   |
| Complex karyotype                    | 58/263 | 22           | 1.90 (1.15-3.14)    | .013                   |
| Cytogenetics and molecular risk       |       |               |                     |                        |
| Favorable                            | 36/263 | 7             | Reference           |                        |
| Intermediate                         | 133/263 | 36          | 1.44 (0.64-3.25)    | .374                   |
| Poor/adverseb                        | 94/263 | 28           | 1.72 (0.75-3.93)    | .201                   |
| Lab data                             |       |               |                     |                        |
| Bone marrow blasts ≥ 70%             | 157/263 | 50         | 1.65 (1.00-2.73)    | .049                   |
| Presence of blasts in peripheral blood | 182/275 | 59      | 1.47 (0.89-2.44)    | .135                   |
| White blood cell count ≥ 100 K/µL    | 26    | 15            | 3.19 (1.82-5.62)    | <.001                  |
| Absolute neutrophil count < 500/µL   | 82    | 19            | 0.72 (0.43-1.20)    | .209                   |
| Hemoglobin < 10 g/dL                 | 231   | 63            | 0.76 (0.44-1.31)    | .320                   |
| Platelets < 20 000/µL                | 45    | 16            | 1.45 (0.84-2.51)    | .184                   |
| eGFR < 45                            | 63/274 | 30           | 2.71 (1.72-4.28)    | <.001                  |

Abbreviations: AML, acute myeloid leukemia; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; APL, acute promyelocytic leukemia; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group performance; eGFR, estimated Glomerular filtration rate; HR, hazard ratio.

aAll factors with P < .1 in the univariate analysis were included in the Cox multivariate analysis.

bPoor/adverse risk was defined as complex (≥3 clonal chromosomal abnormalities), monosomai karyotype, −5, 5q−, −7, 7q−, 11q23 - non t(9;11), inv(3), t(3;3), t(6;9), t(9;22), or FLT3-ITD mutation with wild-type NPM1.
3.5 Causes of early mortality

The direct causes of early death that occurred during this study are summarized in Figure 3. The most common cause was infection (49 patients, 62.0%). Prolonged neutropenia contributed to pneumonia, septic shock, and acute respiratory failure in patients who died early of infection. Five patients had ischemic strokes or intracranial hemorrhage; other bleeding causes included two patients with pulmonary hemorrhage and two patients with massive gastrointestinal bleeding. Acute renal failure occurred in nine patients, in which eight cases had acute kidney injuries and/or tumor lysis syndrome, and one case had central diabetes insipidus due to brain infiltration associated with acute leukemia cells. Cardiogenic shock occurred in four patients; three patients died of acute pulmonary edema without heart evaluation. Sudden death occurred in one patient at AML diagnosis. Four patients died at home or at other institutions and were without detailed information.

4 DISCUSSION

To the best of our knowledge, this is the first study that predicts early mortality of elderly AML patients in Asia and validates other prognostic models developed in Western countries. Based on the prognostic factors, we classified patients into three risk groups. The early mortality rate of low-, intermediate-, and high-risk groups were 10.3%, 26.8%, and 70.7%, respectively. Our results may help physicians stratify patients and initiate proper treatment.

We have systematically reviewed existing AML prognostic scoring systems and evaluated the five prognostic models in our elderly AML cohort. Those AML risk-stratified models used common risk factors, including age, performance
status. Anthracycline treatment might cause cardiomyopathy, cytogenetics, and types of AML. Our model consists of age, myocardial infarction, ECOG, complex karyotype, BM blasts, WBC, and eGFR, which are a part of routine workup for AML at diagnosis. Our model can easily be applied to AML patients in daily practice. In addition, our model had the highest C statistic and the lowest AIC and BIC, in comparison with other prognostic models.

We found that age is a key element of our model and some other models. Elderly patients frequently have multiple comorbidities and have a lower probability of responding to induction treatment. Although our model has adjusted for some age-associated adverse characteristics such as secondary AML and complex karyotypes, old age still negatively impacts patient outcomes. Kantarjian et al compared the outcomes of elderly AML patients stratified by age. They found age ≥ 80 years was an independent adverse prognostic factor for eight-week mortality. Farag et al reported that being age 80 or older doubled the risk of death for AML patients. Performance status is also an important element of disease prognosis, and it was included in all five existing prognostic models and our model. Poor performance status reflects organ dysfunctions. Several studies show that poor performance status is the strongest predictor for OS and treatment-related mortality.

High WBC counts were associated with coagulopathy, pulmonary and CNS leukostasis, and renal failure. Valcarcel et al found that leukocytosis (>100 × 10^9/L) doubled the risk of death during standard induction chemotherapy in newly diagnosed AML patients. A systemic review and meta-analysis shows that early mortality related to hyperleukocytosis in AML is not reversed by leukapheresis or pharmacologic cyto-reduction. Acute renal failure was a common cause of death in previous studies. Low creatinine clearance may increase the toxicity of chemotherapy and other medication. It also contributes to tumor lysis syndrome. Therefore, drug dose adjustment is needed in patients with renal impairment. In the current study, we use eGFR because creatinine differs by sex. Myeloblasts in BM reflect disease burden. Farag et al found a 6% increase of mortality risk with every 1% increase of BM blasts. Complex karyotype is an unfavorable prognostic factor in AML patients. Many studies have shown that complex karyotype can predict a lower chance of achieving CR or post-induction mortality in elderly AML patients. Therefore, elderly AML patients with unfavorable cytogenetics might not benefit from standard therapies. Myocardial infarction is a key prognostic factor for cancer patients. Anthracycline treatment might cause cardiomyopathy and heart failure. The patients with myocardial infarction received less intensive treatment in the current study.

A remarkable study from MD Anderson Cancer Center in 2010 revealed that intensive chemotherapy did not benefit most elderly AML patients. In the study, four of the variables (age, performance status, karyotype, and creatinine) in our model were used to predict the probability of early mortality after receiving intensive chemotherapy. The median survival of elderly AML patients with one, two, and ≥ three risk factors were only 5.3, 1.5, and 0.5 months, respectively. Therefore, they recommend elderly patients with any risk factor not receive intensive chemotherapy.

Our study has some limitations. Our patients did not receive new tests for molecular abnormalities, such as ASXL1, TP53, and RUNX1, which were recommended by the European LeukemiaNet guidelines in 2017. The choice of AML treatment was decided based on patient characteristics and was highly associated with all prognostic factors. Receiving supportive care might be a potential confounding factor in this study. Due to the retrospective nature of this study, our findings may be subject to selection bias, so further validations are warranted.

## Conclusion

Early mortality in elderly AML patients is still common despite the development of novel therapies. It’s crucial to find out the prognostic factors and plan management strategies according to disease risk stratification. Of great importance, we systemically reviewed all current prognostic models and include risk factors suitable for routine practice. We identified seven risk factors of early mortality, including age ≥ 80, myocardial infarction, ECOG ≥ 2, complex karyotype, BM blasts ≥ 70%, WBC ≥ 100 × 10^9/L, and eGFR < 45. Our findings may help clinicians stratify elderly AML patients and initiate appropriate treatment.

## Competing Interests

The authors declare no conflict of interest.

## Acknowledgments

This study was supported by grants from Taipei Veterans General Hospital (V105E10-002-MY2-1 and V105B-016), the Ministry of Science and Technology (MOST 104-2314-B-075-085-MY2 and MOST 105-2314-B-418-003-MY3), the Taiwan Clinical Oncology Research Foundation, the Szu-Yuan Research Foundation of Internal Medicine, the Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang-Ming University, and the Yen Tjing Ling Medical Foundation. The funding sources had no role in the study design or conduct, or in the decision to submit it for publication.

## Authors’ Contributions

C-JL had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy
of the data analysis, C-JL, Y-CH, and C-KT designed the study. C-MY and C-JL acquired the data and performed statistical analysis. C-JL, C-MY, and C-KT provided the final interpretation of the results. C-JL and C-MY drafted the manuscript. Y-CH, A-SK, Y-CL, L-TH, H-YW, and P-SK made critical revisions to the manuscript for important intellectual content. C-JL, C-KT, and C-MY provided administrative, technical, and material support. P-MC, J-HL, and J-PG were the study supervisors. C-JL and J-PG act as guarantors and accept responsibility for the integrity of the work as a whole. All authors have read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
Supplementary information and data are available at Cancer Medicine’s website.

ORCID
Chia-Jen Liu https://orcid.org/0000-0001-7945-9292

REFERENCES
1. Wu SJ, Chiang CI, Lin CT, Tien HF, Lai MS. A nationwide population-based cross-sectional comparison of hematological malignancies incidences between Taiwan and the United States of America. Ann Hematol. 2016;95:165-167.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
3. Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119:3890-3899.
4. Bell JA, Galaznik A, Farrelly E, et al. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. Leuk Res. 2019;78:45-51.
5. Malfuson J-V, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93:1806-1813.
6. Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145:598-605.
7. Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63-73.
8. Pastore F, Dufour A, Benthuis T, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32:1586-1594.
9. Oncological Collaboration (OCTOPUS) working party. New molecular genetic criteria of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22:2076-2082.
10. Potti A, Benezra R. Prognostic value of molecular genetic markers in AML: a comprehensive overview. Cancer. 2005;103:2289-2290.
11. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.
12. Boddu PC, Kantarjian HM, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017;123:3050-3060.
13. Ramos F, Thépot S, Pleyer L, et al. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. Leuk Res. 2015;39:296-306.
14. Valcarcel D, Montesinos P, Sanchez-Ortega I, et al. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. Cancer. 2012;118:410-417.
15. Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098.
16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
17. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55:622-627.
18. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005;23:9219-9226.
19. Greenwood MJ, Sefield MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47:1245-1252.
20. Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63-73.
21. Pastore F, Dufour A, Benthuis T, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2014;32:1586-1594.
22. Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol. 1988;27:34-37.
23. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987;5:1364-1372.
24. Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res. 2008;32:1221-1227.
25. Loboda S, Lehnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014;38:460-468.
26. Chang MC, Chen T-Y, Tang J-L, et al. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007;82:976-980.
27. Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control. 2000;7:548-556.
28. Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk
factors and development of a predictive model. *Haematologica*. 2008;93:67-74.

30. Mato AR, Riccio BE, Qin LI, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. *Leuk Lymphoma*. 2006;47:877-883.

31. Abu-Alfa AK, Younes A. Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management. *Am J Kidney Dis*. 2010;55: (5):S1-S13.

32. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. *Cancer*. 1997;80:1317-1322.

33. Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. *Lancet*. 2010;376:2000-2008.

34. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40:373-383.

35. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. *J Clin Oncol*. 2008;26:3777-3784.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Liu C-J, Hong Y-C, Kuan A-S, et al. The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. *Cancer Med*. 2020;9:1572–1580. [https://doi.org/10.1002/cam4.2740](https://doi.org/10.1002/cam4.2740)